Two Sigma Investments LP purchased a new stake in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 59,950 shares of the biotechnology company’s stock, valued at approximately $159,000.
A number of other hedge funds have also made changes to their positions in PIRS. SG Americas Securities LLC acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $36,000. Prudential Financial Inc. acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $43,000. Alambic Investment Management L.P. acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $59,000. Rhumbline Advisers lifted its position in Pieris Pharmaceuticals by 51.5% during the fourth quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 22,720 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Pieris Pharmaceuticals by 8.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 70,498 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 5,487 shares in the last quarter. 70.73% of the stock is currently owned by hedge funds and other institutional investors.
Shares of PIRS stock opened at $3.10 on Wednesday. The company has a market cap of $152.86 million, a price-to-earnings ratio of -6.20 and a beta of 1.88. Pieris Pharmaceuticals Inc has a fifty-two week low of $2.39 and a fifty-two week high of $6.94.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). The business had revenue of $4.91 million for the quarter, compared to analyst estimates of $6.92 million. Pieris Pharmaceuticals had a negative net margin of 91.93% and a negative return on equity of 54.54%. Equities research analysts predict that Pieris Pharmaceuticals Inc will post -0.81 EPS for the current year.
PIRS has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pieris Pharmaceuticals in a research report on Tuesday, March 19th. Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.38.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: S&P 500 Index
Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.